July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
The Effect of Antiamoebic Agents on Viability, Proliferation and Migration of Human Epithelial Cells, Keratocytes and Endothelial Cells, in vitro
Author Affiliations & Notes
  • Lei Shi
    Department of Ophthalmology, Saarland University Medical Center, Homburg/Saar, Germany
    Department of Ophthalmology, Anhui Provincial Hospital, Hefei, Anhui, China
  • Tanja Stachon
    Department of Ophthalmology, Saarland University Medical Center, Homburg/Saar, Germany
  • Berthold Seitz
    Department of Ophthalmology, Saarland University Medical Center, Homburg/Saar, Germany
  • Stefan Wagenpfeil
    Institute of Medical Biometry, Epidemiology and Medical Informatics, Homburg/Saar, Germany
  • achim langenbucher
    Institute of Experimental Ophthalmology, Homburg/Saar, Germany
  • nora Szentmáry
    Department of Ophthalmology, Saarland University Medical Center, Homburg/Saar, Germany
    Department of Ophthalmology, Semmelweis University, Budapest, Hungary
  • Footnotes
    Commercial Relationships   Lei Shi, None; Tanja Stachon, None; Berthold Seitz, None; Stefan Wagenpfeil, None; achim langenbucher, None; nora Szentmáry, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2261. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lei Shi, Tanja Stachon, Berthold Seitz, Stefan Wagenpfeil, achim langenbucher, nora Szentmáry; The Effect of Antiamoebic Agents on Viability, Proliferation and Migration of Human Epithelial Cells, Keratocytes and Endothelial Cells, in vitro. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2261.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze the effects of diamidines (hexamidine-diisethionat (HD), propamidin-isethionate (PD), dibromopropamidine-diisethionat (DD)) and biguanides (polyhexamethylen biguanid (PHMB), chlorhexidine (CH)) on human corneal epithelial cell, keratocyte and endothelial cell viability, proliferation and migration, in vitro.

Methods : For epithelial and endothelial cells a human cell line, for keratocytes primary cultures were used (n=6 each). We used 3.9x10-4-0.1% HD, PD or DD, 3.9x10-4-0.0125% PD, 7.8x10-5-0.02% PHMB or CH concentration for 24 hours to determine viability with Cell Proliferation Kit XTT, proliferation by Cell Proliferation ELISA BrdU kit and migration using wound healing assay. Viability/proliferation/migration values of each drug were summarized as area under curve (AUC) and a Mann-Whitney test was used.

Results : HCEC, keratocyte and HCEC-12 viability AUC, comparing PD and PHMB (p≤0.014 for all; PD better) or PD and HD (p≤0.011 for all; PD better) differed significantly. Keratocyte and HCEC-12 viability AUC comparing CH and HD (p≤0.027; CH better), HCEC-12 viability AUC comparing PD and HD (p=0.005; PD better) and HCEC viability AUC comparing CH and PHMB (p=0.014; CH better) differed significantly. HCEC proliferation AUC, comparing PD with PHMB, CH, DD, HD (PD worse for all)(p≤0.016 for all) and keratocyte proliferation AUC, comparing PHMB with HD, PD (p=0.004; p=0.002; PHMB better for both), CH with HD, PD (p≤0.001; CH better for both) and DD with PD (p=0.043; DD better) differed significantly. Keratocyte migration AUC comparing PD with control, PHMB, CH, DD and HD differed significantly (p≤0.012; PD worse for all).

Conclusions : Propamidin-isethionate as diamidine and chlorhexidin as biguanide might be used clinically, to reduce cytotoxicity of antiacanthaemoeba treatment on human corneal cells. Diamidines reduce proliferation of human epithelial cells and keratocytes more than biguanides and propamidin-isethionate reduces migration of keratocytes. Therefore, with lower cytotoxicity but inhibitory effect on proliferation and migration, extended use of propamidin-isethionate should be avoided in patients.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×